Business Segments · Segment operating income
Life Sciences: — Segment operating income
STERIS Life Sciences: — Segment operating income increased by 3.2% to $61.80M in Q4 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ3 2024
Last reportedQ4 2025
Rolls up toOperating Income
How to read this metric
An increase demonstrates improved profitability and operational efficiency, while a decrease suggests margin pressure or rising costs within the segment.
Detailed definition
This metric measures the profitability of the Life Sciences segment after accounting for direct costs and allocated oper...
Peer comparison
Comparable to segment operating profit or EBIT reported by diversified medical technology companies.
Metric ID:
ste_segment_life_sciences_segment_operating_incomeHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $53.70M | $58.10M | $59.90M | $61.80M |
| QoQ Change | — | +8.2% | +3.1% | +3.2% |
| YoY Change | — | — | +11.5% | +6.4% |
Range$53.70M – $61.80M
Avg YoY Growth+9.0%
Median YoY Growth+9.0%
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is STERIS's life sciences: — segment operating income?
- STERIS (STE) reported life sciences: — segment operating income of $61.80M in Q4 2025.
- What does life sciences: — segment operating income mean?
- The profit earned by the Life Sciences segment after deducting operating expenses.